Stay updated with breaking news from John Heymach. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R...
Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations...
Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R...
An immunotherapy-targeted therapy combination could offer a new treatment option to patients with non-small cell lung cancer whose tumors have become resistant to other treatments.
A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistanc